ESTRO 37 Abstract book

S76

ESTRO 37

Results Multivariate analysis showed that early stage (HR: 0.41; P=0.049), surgery (HR: 0.33; P=0.003), and concurrent radio(chemo)therapy (HR:0.51;P=0.009) were significantly associated with better overall survival (OS). The HSPB1 rs2868371 CC genotype was associated with better survival compared with the rs2868371 GG/GC genotypes (HR=0.349; 95% CI=0.127-0.964; P=0.042). Two years OS for 72% of patients carrying the rs2868371 CC genotype and 36% for patients with rs2868371 GG/GC genotypes (log-rank test: P=0.013). In addition, the rs2868371 CC genotype was also found to be associated with better disease-free survival (HR: 0.357; 95% CI: 0.128-0.991; P=0.048). Conclusion Our findings validate a strong relationship between the functional HSPB1 promoter variant rs2868371 and OS among NSCLC patients. High expression of HSPB1 can mediate cancer progression through inhibition of the programmed cell death and senescence in lung cancer. A plausible explanation for a better OS in patients carrying the C allele may rely on the presence of a functional binding site in this region where the C allele prompt to a lower transcription factor-DNA binding affinity responsible of a cascade of downstream events able to alter endogenous HSPB1 expression levels. OC-0154 REQUITE Big Data Resource for Validating Predictive Models and Biomarkers of Radiotherapy Toxicity C. West 1 , R. Elliott 1 , C. Talbot 2 , A. Webb 2 , P. Seibold 3 , D. Azria 4 , D. De Ruysscher 5 , R. Symonds 6 , L. Veldeman 7 , B. Rosenstein 8 , P. Lambin 5 , T. Burr 9 , S. Gutiérrez Enríquez 10 , T. Rancati 11 , A. Vega 12 , J. Chang-Claude 3 1 The University of Manchester, Division of Cancer Sciences, Manchester, United Kingdom 2 University of Leicester, Department of Genetics, Leicester, United Kingdom 3 German Cancer Research Center DKFZ, Division of Cancer Epidemiology, Heidelberg, Germany 4 Montpellier Cancer Instiute, Department of Radiation Oncology, Montpellier, France 5 Maastricht University Medical centre, Department of Radiation Oncology, Maastricht, The Netherlands 6 University of Leicester, Department of Cancer Studies, Leicester, United Kingdom 7 Gent University Hospital, Radiation Oncology Department, Ghent, Belgium 8 Icahn School of Medicine at Mount Sinai-, Department of Radiation Oncology, New York, USA 9 University of Nottingham, Source Bioscience, Nottingham, United Kingdom 10 Vall d’Hebron Institute of Oncology-VHIO, Oncogenetics Group, Barcelona, Spain 11 Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Cancer Program, Milan, Italy 12 Fundacion Publica Galega de Medicina Xenomica- SERGAS, Grupo de Medicina Xenomica-USC, Santiago de Compostela, Spain Purpose or Objective Many models and biomarkers were reported to have potential to predict a cancer patients’ risk of toxicity following radiotherapy (RT), but the challenge is to validate them for clinical application. Validation requires access to well-annotated big datasets. The European Union funded FP7 REQUITE project was established with the aim of carrying out a prospective, longitudinal, multi- centre study to compile a large centralised, standardised dataset and biorepository for validating models and biomarkers that predict a cancer patient’s risk of RT toxicity. Material and Methods Case record forms were produced to collect standardised epidemiology, treatment, side effect and quality-of-life

data from patients recruited in 12 main centres in Belgium, France, Germany, Italy, Spain, The Netherlands, UK and USA. Questionnaires for collecting patient reported Common Toxicity Criteria for Adverse Events were translated into multiple languages and validated for use. Data are collected both prior to RT and post-RT and at years 1 and 2. A centralised biorepository stores DNA and PAXgene tubes. The radiation induced lymphocyte assay (RILA) was carried out in three centres (France, Germany, UK). Results 4,440 patients were recruited prospectively and an additional 383 lung cases identified and included to bring the total in the resource to 4,823 (91% of the planned 5,300). Prospective recruitment over the time possible during the funding period was highest for breast (2,071 of 2,100 planned) then prostate (1,810 of 2,100 planned) and lung (559 of 1,100 planned). The quality controlled centralised database for electronic data capture and storage contains a considerable amount of data (>80,000 completed case record forms) and includes dose volume histograms for 4,125 (93% of total) and DICOM files for 4,170 (94% of total) patients. Breast photos taken at baseline and two years to score change in appearance are also stored: 2,039 photos at baseline (98%) and currently 704 photos at two years. RILA data were collected for 1,322 patients. A centralised biobank repository contains DNA from 4,450 patients and 3,128 PAXgene tubes, which are available for future studies. Infinium OncoArray-500K SNP genotyping is underway for all samples, and the genomics data will be available for export via a data portal. A process was established to provide access to the resource via submission of a concept form, and a public discovery platform (Café Variome) will be available in 2018 enabling researchers to query the REQUITE database. Conclusion REQUITE has developed a standardised approach for collecting and curating RT data linked with a biorepository. The outputs of REQUITE are already serving as resource for REQUITE partners and the wider radiobiology community. OC-0155 The effect of accelerated partial breast irradiation on quality of life. D.H.M. Jacobs 1 , N. Horeweg 1 , M. Straver 2 , E.M.A. Roeloffzen 3 , G. Speijer 4 , J. Merkus 5 , J. Van der Sijp 2 , M.E. Mast 6 , U. Fisscher 6 , A.L. Petoukhova 6 , A.G. Zwanenburg 3 , C.A.M. Marijnen 1 , P.C.M. Koper 6 1 Leiden University Medical Center LUMC, Radiotherapy, Leiden, The Netherlands 2 Haaglanden Medical Center, Surgery, The Hague, The Netherlands 3 Isala, Radiotherapy, Zwolle, The Netherlands 4 Haga Hospital, Radiotherapy, The Hague, The Netherlands 5 Haga Hospital, Surgery, The Hague, The Netherlands 6 Haaglanden Medical Center, Radiotherapy, The Hague, The Netherlands Purpose or Objective To investigate health related quality of life (HRQL) in elderly breast cancer patients after two types of Accelerated Partial Breast Irradiation: intraoperative radiotherapy (IORT) and external beam APBI (EB-APBI). Material and Methods Between 2011 and 2016 women ≥60 years with breast tumours of ≤30 mm undergoing breast conserving therapy were included in a prospective multi-centre cohort study. Patients were treated with electron IORT (1x23.3 Gy prescribed at 100% isodose) (n=268) or photon EB-APBI (10x3.85 Gy daily approximately 4 weeks after surgery) Proffered Papers: CL 3: Breast